Design Therapeutics, Inc. DSGN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Design Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Design Therapeutics, Inc.'s cash & equivalents?
- Design Therapeutics, Inc. (DSGN) reported cash & equivalents of $12.77M in Q1 2026.
- How has Design Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Design Therapeutics, Inc.'s cash & equivalents decreased by 6.6% year-over-year, from $13.67M to $12.77M.
- What is the long-term trend for Design Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Design Therapeutics, Inc.'s cash & equivalents has grown at a 47.9% compound annual growth rate (CAGR), from $2.38M to $16.86M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.